| NCT ID | NCT05910268 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,450 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,450 participants in total. It began in 2024-04-01 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand the processes by which HIV care is decentralized, an evidence-informed strategy to improve retention in HIV care, in Peru. Decentralization of HIV services has not been evaluated using experimental designs and urban decentralization studies of HIV are uncommon, so this study will lend important insights for future decentralization efforts in Peru and other countries.
Eligibility Criteria
Inclusion Criteria for Aim 3: Survey of PHC and SHC Clinicians (N=330): * Currently employed at a PHC or SHC that is participating in the study. Provide consent for participation. Continuing Professional Development (N=825): * Currently employed as a nurse or physician who fulfilled the ECHO training requirements Survey of PHC Leadership (N=165): * Currently serving as the leader of a PHC.
Contact & Investigator
Frederick Altice, M.D., M.A.
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT05910268 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05910268 currently recruiting?
Yes, NCT05910268 is actively recruiting participants. Contact the research team at frederick.altice@yale.edu for enrollment information.
Where is the NCT05910268 trial being conducted?
This trial is being conducted at New Haven, United States, Bellavista, Peru.
Who is sponsoring the NCT05910268 clinical trial?
NCT05910268 is sponsored by Yale University. The principal investigator is Frederick Altice, M.D., M.A. at Yale University. The trial plans to enroll 1,450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.